WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202524323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Taiki Yamazaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translational Research for Biologics, Department of Advanced Medical and Pharmaceutical Sciences, Kobe University Graduate School of Sc…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Bifidobacterium longum, Cancer Vaccines, WT1 Proteins. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immune checkpoint inhibitors (ICI) due to its profoundly immunosuppressive tumor microenvironment. To overcome this resistance, we evaluated an oral WT1‐targeted cancer vaccine using a recombinant Bifidobacterium longum strain ( B. longum 420) engineered to display a partial WT1 antigen. Oral immunization with B. longum 420 activated WT1‐associated cellular immunity, increasing IL‐12–producing CD45 + cells and Th1/cytotoxic cytokine‐producing T cells, and enhancing splenocyte cytotoxic activity against Pan02 cells. In a syngeneic Pan02 tumor model, the combination of B. longum 420 with anti‐PD‐1 and anti‐CTLA‐4 antibodies resulted in stronger antitumor effects and improved survival compared with each monotherapy, without marked body weight loss. An empty‐vector control strain did not further enhance the efficacy of dual checkpoint blockade. Tumor analyses showed increased intratumoral CD8 + T cell density and expansion of effector, central memory, and PD‐1 + Ki‐67 + proliferating CD8 + subsets, together with treatment‐dependent differences in intratumoral CD4 + T cell subset composition. These findings demonstrate that an oral WT1‐targeted Bifidobacterium vaccine can potentiate dual checkpoint blockade and promote a more immunologically active T cell landscape in PDAC. To our knowledge, this is the first demonstration of this combination strategy in a syngeneic pancreatic cancer model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Translational Research for Biologics, Department of Advanced Medical and Pharmaceutical Sciences, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan.
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Toshiro Shirakawa
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Yamazaki, T., Minami, A., Hirota, M., Hirano, M., Sato, R., Honma, A., Ueki, H., & Shirakawa, T. (2026). WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer. Advanced Science. https://doi.org/10.1002/advs.202524323
Vancouver
Yamazaki T, Minami A, Hirota M, Hirano M, Sato R, Honma A, et al. WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer. Advanced Science. 2026. doi:10.1002/advs.202524323
BibTeX
@article{Yamazaki2026,
author = {Yamazaki, Taiki and Minami, Aori and Hirota, Misako and Hirano, Mirei and Sato, Ryota and Honma, Atsuki and Ueki, Hideto and Shirakawa, Toshiro},
title = {WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202524323}
}
EUVIMED